Market Overview

UPDATE: Credit Suisse Reiterates Outperform Rating, Lowers PT on Teva Pharmaceutical Industries

Related TEVA
Teva, Heptares Announce Agreement to Discover and Develop Novel, Small-Molecule CGRP Antagonists for Treatment of Migraine
Benzinga's Top Upgrades
Ad Comm approaches for Fabre-Kramer's MDD med (Seeking Alpha)

In a report published Monday, Credit Suisse Group reiterated its Outperform rating on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), but slightly lowered its price target from $51.00 to $50.00.

Credit Suisse noted, “We would be buyers of Teva shares ahead of the Dec. 11th investor day. Teva's 2013 guidance of $4.85-$5.15 was well below consensus and our expectations; however, our overall impression from the co.'s call was positive. Teva has set a new, makeable bar for 2013, and has shown increased transparency in its guidance. The co.'s 2013 guidance dispenses with the market's apprehension about "how low" the numbers would be, and allows the company to focus investor attention at the Dec. 11th event on several more positive, long-term topics: (1) portfolio strategy (including business development and pipeline details); (2) capital allocation; and (3) details on the newly announced $1.5 - $2.0 Bn cost cut program.”

Teva Pharmaceutical Industries Ltd. closed on Friday at $40.35.

Latest Ratings for TEVA

Nov 2015Goldman SachsUpgradesNeutralBuy
Sep 2015NomuraInitiates Coverage onNeutral
Aug 2015Goldman SachsReinstatesBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Credit Suisse GroupAnalyst Color Price Target Analyst Ratings


Related Articles (TEVA)

Get Benzinga's Newsletters